Teva says FDA approves at-home Igalmi for acute agitation
The expanded prescription indication covers adults with specified psychiatric conditions, while the company has yet to announce its rollout plans.
How this story was made
This story was written with AI assistance from Teva Pharmaceuticals’s own announcement. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.
Not investment advice.
The November 16 announcement concerns dexmedetomidine in a sublingual film. Teva describes it as the first FDA-approved treatment specifically available for self-administration at home during agitation episodes associated with those conditions. It remains a prescription medicine.
A trial poster filed with the Securities and Exchange Commission describes the evidence behind the change: a randomized, double-blind, placebo-controlled study lasting 12 weeks, with safety and tolerability as its primary objective. Investigators randomized 246 people; 208 subsequently treated at least one agitation episode.
Within that treated group, 102 people received the active medicine for 1,160 episodes. The placebo group treated 1,277 episodes. Those are repeated episodes within participants, so the study should not be read as evidence from thousands of different patients.
The poster reports that adverse-event frequency did not increase with repeated administration and that no participant receiving the active medicine stopped because of a treatment-emergent adverse event. Its symptom assessments were exploratory, and the study was not powered to establish efficacy.
Participants were adults already on a stable psychiatric medication regimen who had a history of agitation. The researchers excluded people with specified unstable or serious medical illnesses and several other conditions. That selection matters when interpreting how broadly a trial’s experience might apply.
Teva lists sleepiness, dry mouth, dizziness and altered sensation in the mouth among the common adverse effects in the home setting. Its safety information also warns of low blood pressure, including after standing, and a slow heart rate.
For patients and caregivers, approval is one step in access. Teva, which acquired Igalmi in late October, says it will announce commercialization plans later; its announcement does not set an at-home launch date or price.
End of story


